AdobeStock_399705065.jpeg
Welcome to Bio5C

We produce independent and unbiased equity research on biotechnology and pharmaceutical stocks based on our proprietary 5 Cs of Biotech™ model. 

What are The 5 Cs of Biotech Investing™?
The 5 Cs are:
Charisma, Credibility, Catalysts, Cash, and Capital Structure

Bio5C analysis is designed to help you make an informed investment decision by using our proprietary research. The 5C model has been proven effective in picking winners in the biopharma market. In 2019, the Bio5C Model Portfolio increased +76% compared to +33% for the XBI and +29% for the SPY.

 

In 2020, a mix of the Bio5C Model Portfolio increased +53% compared to +48% for the XBi and +16% for the SPY. And in 2021, a difficult year for biopharma investors, Bio5C Model Portfolio lost 10.1%, a disappointment, but still above the XBI benchmark that was down 21%. Over the past three years, dating back to January 2019, the Bio5C Model is +111% vs. the XBI at +56%.

Get Started Today.
AdobeStock_314902938.jpeg
AdobeStock_314902938.jpeg

At Bio5C, we not only identify winners, but the model is also effective in keeping you from investing in potential losers (or identifying short ideas). Throughout the history of the 5C model, the highest-scoring stocks have consistently outperformed the lowest scoring stocks. You can learn more about the success of our model under the About tab. 

Bio5C subscribers have access to the 5C Model, a Model Portfolio based on the 5Cs coupled with our valuation analysis, and detailed research and analysis on all stocks in our Coverage Universe, which includes audio podcasts and Video reports. We also have a Stock Forum for quick news and analysis of individual stocks and a Slack Board where members can interact and ask questions, discuss recent posts, get alerts on trades, and learn! Visit the Subscribe tab to learn more! 

 

We invite you to check out Free samples of our work above, and if you have any questions about our subscription service, please contact us for more information.

Table-Redesign_Bio5C_rev3-22-01.png

Bio5C also offers truly independent and unbiased equity research analysis. Our models include the 5C score and quick overview of the technology or platform, an analysis of each key product candidate, including the preclinical and clinical data, the revenue market opportunity for each candidate, a full valuation, technical analysis, and a price target recommendation. 

About Jason

Bio5C also offers truly independent and unbiased equity research analysis. Our models include the 5C score and quick overview of the technology or platform, an analysis of each key product candidate, including the preclinical and clinical data, the revenue market opportunity for each candidate, a full valuation, technical analysis, and a price target recommendation. 

  • Twitter
@juliaskripkaser

At Bio5C, we not only identify winners, but the model is also effective in keeping you from investing in potential losers (or identifying short ideas). Throughout the history of the 5C model, the highest-scoring stocks have consistently outperformed the lowest scoring stocks. You can learn more about the success of our model under the About tab. 

  • Twitter
@frandanconia

Awesome weekly review Jason. Really enjoyed hearing the bearish side as it’s an essential part of due diligence. Really happy with your service.

  • Twitter
@qfam7

These weekly reviews keep getting better. Without a doubt the most comprehensive coverage for biotech investors out there and luckily, it’s available to the general public. We all would be paying out the ear for banker coverage if it were not for your service.